In another study assessing multiple myeloma patients that remained in complete remission more than 6 years after APBHSCT, Arteche-Lopez et al. reported fewer activating receptors such as NKp46 together with increased expression of inhibitory NKG2A and KIR2DL1 receptors [48]. The gene discussed is KLRC1; the disease is plasma cell myeloma.